Nivolumab in advanced lung cancer: Indication of major added benefit

Patients with advanced nonsquamous NSCLC who have already undergone chemotherapy survive longer with the drug Nivolumab than with docetaxel.
Source: ScienceDaily Headlines - Category: Science Source Type: news